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Dear Sir,
Keloids are thick, raised scars that represent an extreme form of abnormal scarring.
Unlike normal scars, keloids extend beyond the original wound margin and rarely regress;
instead, they tend to proliferate indeﬁnitely.1-4 These bulky scars can signiﬁcantly impair
function due to itching, pain, and decreased range of motion5 and can negatively impact
psychosocial well-being and overall quality of life.5-7 Although many different therapeu-
tic modalities exist, keloids are extremely resistant to treatment and have a high rate of
recurrence.1,2,8-10 Development of effective, targeted interventions has been limited due
to an incomplete understanding of the pathophysiology of keloid scarring. Furthermore,
because keloid scarring is only found in humans, there are no animal models of keloid scar-
ring, which has hindered the evaluation of novel therapies. Ethical considerations preclude
wound healing studies in patients susceptible to keloid scarring. Therefore, in the absence
of suitable animal models, organotypic models represent a feasible alternative for investi-
gation of wounding in keloid tissue. In the current study, we investigated engineered skin
substitutes (ESS) composed of keratinocytes, ﬁbroblasts, and collagen-glycosaminoglycan
biopolymers, as an in vitro organotypic keloid model to analyze changes in gene expression
in response to wounding.
Primary human ﬁbroblasts and keratinocytes were isolated and cultured11,12 from
excised keloid scar or normal skin, collected with University of Cincinnati Institutional
Review Board approval. ESS were prepared by sequential inoculation of ﬁbroblasts
and keratinocytes onto approximately 40 cm2 collagen-glycosaminoglycan biopolymer
sponges.11,13,14 After 7 days of culture at the air-liquid interface, ESS were cut in half, and
one piece of each was wounded using a skin graft mesher; approximation of the cut edges
permitted healing of the wounded ESS to occur.
Histological analysis of sections of normal and keloid ESS 14 days after keratinocyte
inoculation demonstrated a well-stratiﬁed epidermal layer and a dermal component
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populated with ﬁbroblasts (Figs 1a-1f). Seven days after wounding, migration of ker-
atinocytes into the wound edge occurred to varying degrees in both normal and wounded
ESS. In keloid ESS, newly synthesized collagen was visible in the area adjacent to the
wound, as evidenced qualitatively in trichrome-stained sections. This was not observed in
the normal ESS after wounding.
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Figure 1. Histological analysis of normal and keloid ESS. (a-f), Representative formalin-ﬁxed,
parafﬁn-embedded sections of ESS from day 14 of in vitro incubation, stained with Masson’s
trichrome. (a) Nonwounded normal ESS. (b-c), Wounded normal ESS. (d), Nonwounded keloid
ESS. (e-f) Wounded keloid ESS. In these sections, the epidermal layer stains dark reddish-pink; cell
nuclei stain reddish-pink to reddish-blue; the reticulations of bovine collagen from the biopolymer
sponge material stain dark blue; and the newly synthesized human collagen stains bright greenish-
blue. Locations of “healing” wounds in b, c, e, f indicated by arrows. Note the increased collagen
deposition in the wounded keloid ESS (asterisks) compared with control unwounded or normal
wounded ESS. (g-j) Immunohistochemical localization of periostin, a matricellular protein involved
in collagen ﬁbril formation, in frozen sections of normal (g-h) and keloid (i-j) ESS. The levels
of periostin were below detection in control non-wounded normal (g) or wounded normal ESS
(h), and were low in nonwounded keloid ESS (i). However, periostin signal was readily detected
in keloid ESS after wounding (j) and was localized to the upper dermis and dermal-epidermal
junction in the region of the healing wound (brown staining; arrow). Immunohistochemical staining
ofcontrolsections,withoutprimaryantibody,showednopositivesignal(datanotshown).Scalebars
= 200 μm in all sections.
Immunohistochemistry was performed to localize periostin, a matricellular protein
that has been shown to be expressed at higher levels in keloid ﬁbroblasts than in normal
ﬁbroblasts.15 In contrast to normal ESS or nonwounded keloid ESS, high levels of periostin
were detected in wounded keloid ESS and were localized to the upper dermis and dermal-
epidermal junction in the region of the healing wound (Figs 1g and 1h).
Quantitative real-time PCR16,17 was used to analyze expression of genes previously
implicated in keloid scarring: type 1 collagen pro-alpha 1 and 2 chain genes (COL1A1
and COL1A2); matrix metalloproteinases 1 and 3 (MMP1 and MMP3); and periostin
(POSTN)15,18-22 (Fig2).ExpressionlevelsforCOL1A1,COL1A2,andPOSTNwerehigher
in nonwounded keloid ESS than in nonwounded normal ESS. Upon in vitro wounding,
expression of these genes was slightly elevated in normal ESS but the differences were
not statistically signiﬁcant. In contrast, COL1A1, COL1A2, and POSTN expression levels
were signiﬁcantly increased in wounded keloid ESS. MMP1 and MMP3 were expressed at
lower levels in keloid ESS compared with normal ESS and were not signiﬁcantly increased
after wounding.
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Figure 2. ExpressionofCOL1A1,COL1A2,POSTN,MMP1,andMMP3mRNA
wasquantiﬁedusingrealtimePCR.Expressionlevelswerenormalizedtothelevel
for one nonwounded normal ESS sample, and mean normalized levels + standard
error of the mean are plotted. Expression of COL1A1, COL1A2, and POSTN
was higher in nonwounded keloid ESS compared with normal ESS. Upon in vitro
wounding, no signiﬁcant difference was observed in normal ESS, but COL1A1,
COL1A2, and POSTN expression levels were signiﬁcantly increased in wounded
keloid ESS (
∗
P < 0.05). MMP1 and MMP3 were expressed at lower levels in
keloid ESS compared with normal ESS, and were increased in keloid ESS after
wounding, but the differences were not statistically signiﬁcant. The mean MMP1
and MMP3 levels in wounded keloid ESS were lower than in nonwounded or
wounded normal ESS. Statistical analysis was performed using repeated measures
analysis of variance.
The results obtained using ESS as an in vitro organotypic model are consistent with
the hypothesisthatan imbalanceof extracellularmatrix (ECM) productionand degradation
after wounding leads to keloid scarring. In our organotypic model, keloid cells respond to
injurywithanexaggeratedincreaseinECMproduction.Theexpressionofgenesinvolvedin
ECM breakdown is insufﬁcient to counteract this signiﬁcant increase in matrix production.
We propose that this in vitro model will provide a useful system for further identiﬁcation of
abnormal interactions between keloid ﬁbroblasts, keratinocytes, and ECM, and screening
of novel therapies.
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